WP Thyroid — Class II drug recall D-1609-2020
Terminated recall by RLC Labs Inc., reported 2020-09-23, distributed nationwide. CGMP Deviations: manufactured under the same conditions as those found to be subpotent.
| Recall number | D-1609-2020 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | RLC Labs Inc., Phoenix, AZ, United States |
| Recall initiated | 2020-08-25 |
| Classified | 2020-09-24 |
| Reported by FDA | 2020-09-23 |
| Terminated | 2023-11-08 |
| Distributed | Nationwide (US) |
| Reason classes | potency, cgmp |
| NDC | 64727-5750-01, 64727-5750-02, 64727-5750-04, 64727-5750-05, 64727-5750-06 |
Product
WP Thyroid, Westhroid Pure, 1 Grain (65 mg) Thyroid USP, packaged in a) 1,000 Tablets, NDC 64727-5750-2 ; b) 30 Tablets, NDC 64727-5750-4; c) 60 Tablets, NDC 64727-5750-5; d) 90 Tablets, NDC 64727-5750-6; e) 100 Tablets, NDC 64727-5750-1; Rx only, Manufactured by: RLC Labs Phoenix, AZ 85034
Reason for recall
CGMP Deviations: manufactured under the same conditions as those found to be subpotent.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-1609-2020. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.